CRDF vs. ARVN, OLMA, KOD, ATYR, AQST, ESPR, IVA, RAPP, CYRX, and ZVRA
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Arvinas (ARVN), Olema Pharmaceuticals (OLMA), Kodiak Sciences (KOD), aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), CryoPort (CYRX), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs. Its Competitors
Cardiff Oncology (NASDAQ:CRDF) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.
Cardiff Oncology has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500.
In the previous week, Arvinas had 4 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for Arvinas and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.73 beat Arvinas' score of 1.59 indicating that Cardiff Oncology is being referred to more favorably in the media.
Cardiff Oncology has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Arvinas has a net margin of -19.47% compared to Cardiff Oncology's net margin of -9,344.14%. Arvinas' return on equity of -12.01% beat Cardiff Oncology's return on equity.
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 7.7% of Cardiff Oncology shares are held by company insiders. Comparatively, 4.7% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cardiff Oncology presently has a consensus target price of $10.63, indicating a potential upside of 418.29%. Arvinas has a consensus target price of $19.76, indicating a potential upside of 155.34%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Arvinas.
Summary
Cardiff Oncology and Arvinas tied by winning 8 of the 16 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 9/12/2025 by MarketBeat.com Staff
